For adults with neuromyelitis optica spectrum disorder (NMOSD), rituximab and Uplizna (inebilizumab) work equally well to prevent disease relapses, but Uplizna appears to be safer because it causes fewer infusion-related side effects. Those are the main findings of a real-world study analyzing data from more than 250 NMOSD…
Discussion
I’m a self-sabotaging, push-the-limits kind of gal. The worst kind of patient. The sort of patient doctors warn their interns about. Yes, I know I should be following their recommendations, nodding politely when I’m told what to do, but my neurologist and I both know that I probably won’t listen.
Treatment with Enspryng (satralizumab) for more than two years was shown to prevent relapses in most people with neuromyelitis optica spectrum disorder (NMOSD) in Japan. That’s according to a new study that tracked outcomes from Japanese NMOSD patients given the approved injection therapy in real-world practice. “Overall, most…
NMOSD is a progressive autoimmune disease where the immune system mistakenly attacks nerve cells, affecting the nervous system. Learn more about the disease here.
Scientists do not know the exact underlying cause of NMOSD. Self-reactive antibodies that target AQP4 are known to play a major role. Learn more about what causes the disease here.
When the disease affects the optic nerve (optic neuritis), it can result in pain inside the eye and possibly blurry vision or vision loss. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
